Genmab — Maj 2014
-
Det ser ud til at de er blevet mere strikse mht. patientindrulning i phase II delen. alle pateinter i fase I delen står som prior lines of therapy med 3 hvorimod de 9 patienter i phase II delen indtil videre kun har 1 i prior lines of therapy
s -
så ser ud til de går efter mere raske patienter i phase II delen?
-
Læg i øvrigt mærke til at de 2 patienter der har fået længere behandling med 16 mg. også har en 100% sænkning af paraproteinmængden. Det lover godt
-
Ibrutinib + ofa er på med poster i dag
http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=851587 -
"We are especially encouraged to see that with proper dosing sequence, heavily pretreated CLL/SLL patients on this study have achieved 100% response rates which are lasting over long durations."
-
Det siger det hele.... De kombi data er vildt vildt gode. ikke nok med der er høj responsrate, duration of responserne er vildt lange.... de må for helvede få lavet det phase III snart så de kan vise at de er Ibrutinib+Rituxan overlegen
-
Heldigivis har gilead nosset sig sammen med idelalisib
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind